Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial

 
• By Joseph Haas
  
Clostridium difficile bacteria, 3D illustration. Spore-forming bacteria that cause pseudomembraneous colitis and are associated with nosocomial antibiotic resistance
Seres hopes to improve the standard of care in recurrent C. diff with a microbiome therapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D